{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T07:27:54Z","timestamp":1789975674561,"version":"4.0.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000102","name":"Health Resources and Services Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"Department of Health and Human Services","doi-asserted-by":"publisher","award":["R40MC22641"],"award-info":[{"award-number":["R40MC22641"]}],"id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MIND Institute Intellectual and Developmental Disability Research Center","award":["U54HD07125"],"award-info":[{"award-number":["U54HD07125"]}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1 TR000002"],"award-info":[{"award-number":["UL1 TR000002"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Fragile Foundation\u2019s Rosen\/Weingarden Summer"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","brainanddevelopment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain and Development"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.braindev.2017.01.012","type":"journal-article","created":{"date-parts":[[2017,2,27]],"date-time":"2017-02-27T03:46:24Z","timestamp":1488167184000},"page":"483-492","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Molecular biomarkers predictive of sertraline treatment response in young children with fragile X syndrome"],"prefix":"10.1016","volume":"39","author":[{"given":"Reem Rafik","family":"AlOlaby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan R.","family":"Sweha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisol","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blythe","family":"Durbin-Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn M.","family":"Yrigollen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalyir","family":"Pretto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randi J.","family":"Hagerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Tassone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.braindev.2017.01.012_b0005","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1352\/2008.113:427-438","article-title":"Autism profiles of males with fragile X syndrome","volume":"113","author":"Harris","year":"2008","journal-title":"Am J Ment Retard"},{"key":"10.1016\/j.braindev.2017.01.012_b0010","series-title":"Fragile X Syndrome: diagnosis, treatment, and research","first-page":"3","author":"Hagerman","year":"2002"},{"key":"10.1016\/j.braindev.2017.01.012_b0015","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.neuron.2015.06.017","article-title":"Altered neuronal and circuit excitability in fragile X syndrome","volume":"87","author":"Contractor","year":"2015","journal-title":"Neuron"},{"key":"10.1016\/j.braindev.2017.01.012_b0020","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/1531-8249(199903)45:3<287::AID-ANA3>3.0.CO;2-9","article-title":"Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children","volume":"45","author":"Chugani","year":"1999","journal-title":"Ann Neurol"},{"key":"10.1016\/j.braindev.2017.01.012_b0025","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/YCO.0000000000000131","article-title":"Treatment of the psychiatric problems associated with fragile X syndrome","volume":"28","author":"Hagerman","year":"2015","journal-title":"Curr Opin Psychiatry"},{"key":"10.1016\/j.braindev.2017.01.012_b0030","doi-asserted-by":"publisher","first-page":"110","DOI":"10.5582\/irdr.2014.01027","article-title":"Serotonin dysregulation in fragile X syndrome: implications for treatment","volume":"3","author":"Hanson","year":"2014","journal-title":"Intractable Rare Dis Res"},{"key":"10.1016\/j.braindev.2017.01.012_b0035","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s10882-008-9123-7","article-title":"Results of a nation-wide survey evaluating psychotropic medication use in fragile X syndrome","volume":"21","author":"Valdovinos","year":"2009","journal-title":"J Dev Phys Disabil"},{"key":"10.1016\/j.braindev.2017.01.012_b0040","first-page":"104317","article-title":"Sertraline may improve language developmental trajectory in young children with fragile X syndrome: a retrospective chart review","volume":"2012","author":"Indah Winarni","year":"2012","journal-title":"Autism Res Treat"},{"key":"10.1016\/j.braindev.2017.01.012_b0045","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1089\/cap.1997.7.9","article-title":"Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder","volume":"7","author":"Steingard","year":"1997","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.braindev.2017.01.012_b0050","first-page":"75","article-title":"Emerging pharmacologic treatment options for fragile X syndrome","volume":"8","author":"Schaefer","year":"2015","journal-title":"Appl Clin Genet"},{"key":"10.1016\/j.braindev.2017.01.012_b0055","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s40265-016-0542-y","article-title":"Pharmacotherapy for fragile X syndrome: progress to date","volume":"76","author":"Davenport","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.braindev.2017.01.012_b0060","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.biopsych.2012.06.008","article-title":"Activation of 5-HT7 serotonin receptors reverses metabotropic glutamate receptor-mediated synaptic plasticity in wild-type and FMR1 knockout mice, a model of fragile X syndrome","volume":"72","author":"Costa","year":"2012","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.braindev.2017.01.012_b0065","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1152\/jn.90558.2008","article-title":"Altered hippocampal synaptic plasticity in the FMR1 gene family knockout mouse models","volume":"101","author":"Zhang","year":"2009","journal-title":"J Neurophysiol"},{"key":"10.1016\/j.braindev.2017.01.012_b0070","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1542\/peds.2008-0317","article-title":"Advances in the treatment of fragile X syndrome","volume":"123","author":"Hagerman","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.braindev.2017.01.012_b0075","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fncel.2015.00055","article-title":"Targeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromes","volume":"9","author":"Wang","year":"2015","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.braindev.2017.01.012_b0080","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3004214","article-title":"Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial","volume":"4","author":"Berry-Kravis","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.braindev.2017.01.012_b0085","doi-asserted-by":"publisher","first-page":"158","DOI":"10.5582\/irdr.2016.01045","article-title":"Review of targeted treatments in fragile X syndrome","volume":"5","author":"Ligsay","year":"2016","journal-title":"Intractable Rare Dis Res"},{"key":"10.1016\/j.braindev.2017.01.012_b0090","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/DBP.0000000000000334","article-title":"A randomized double-blind, placebo-controlled trial of low-dose sertraline in young children with fragile X syndrome","volume":"37","author":"Greiss Hess","year":"2016","journal-title":"J Dev Behav Pediatr"},{"key":"10.1016\/j.braindev.2017.01.012_b0095","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1038\/nn1765","article-title":"Fragile X syndrome and autism at the intersection of genetic and neural networks","volume":"9","author":"Belmonte","year":"2006","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.braindev.2017.01.012_b0100","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jpsychires.2014.07.011","article-title":"Impact of acamprosate on plasma amyloid-b precursor protein in youth: a pilot analysis in fragile X syndrome-associated and idiopathic autism spectrum disorder suggests a pharmacodynamic protein marker","volume":"59","author":"Erickson","year":"2014","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.braindev.2017.01.012_b0105","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1002\/ajmg.a.36023","article-title":"High MMP-9 activity levels in fragile X syndrome are lowered by minocycline","volume":"161A","author":"Dziembowska","year":"2013","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.braindev.2017.01.012_b0110","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00213-013-3022-z","article-title":"Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome","volume":"228","author":"Erickson","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.braindev.2017.01.012_b0115","first-page":"28","article-title":"The clinical global impressions scale: applying a research tool in clinical practice","volume":"4","author":"Busner","year":"2007","journal-title":"Psychiatry"},{"key":"10.1016\/j.braindev.2017.01.012_b0120","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/aur.196","article-title":"MAOA, DBH and SLC6A4 variants in CHARGE: a case control study of autism spectrum disorders","volume":"4","author":"Tassone","year":"2011","journal-title":"Autism Res"},{"key":"10.1016\/j.braindev.2017.01.012_b0125","series-title":"R: a language and environment for statistical computing","author":"R. CoreTeam","year":"2016"},{"key":"10.1016\/j.braindev.2017.01.012_b0130","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/DBP.0b013e318287cd17","article-title":"A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile X syndrome","volume":"34","author":"Leigh","year":"2013","journal-title":"J Dev Behav Pediatr"},{"key":"10.1016\/j.braindev.2017.01.012_b0135","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.neulet.2013.06.033","article-title":"Neuroprotective and procognitive effects of sertraline: in vitro and in vivo studies","volume":"550","author":"Taler","year":"2013","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.braindev.2017.01.012_b0140","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1017\/S0954579411000046","article-title":"Perceived discrimination, serotonin transporter linked polymorphic region status, and the development of conduct problems","volume":"23","author":"Brody","year":"2011","journal-title":"Dev Psychopathol"},{"key":"10.1016\/j.braindev.2017.01.012_b0145","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1017\/S0954579414001266","article-title":"5HTTLPR genotype moderates the longitudinal impact of early caregiving on externalizing behavior","volume":"27","author":"Gatzeva-topalova","year":"2015","journal-title":"Dev Psychopathol"},{"key":"10.1016\/j.braindev.2017.01.012_b0150","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1017\/S0954579411000769","article-title":"Interaction of serotonin transporter linked polymorphic region and childhood neglect on criminal behavior and substance use for males and females","volume":"24","author":"Vaske","year":"2012","journal-title":"Dev Psychopathol"},{"key":"10.1016\/j.braindev.2017.01.012_b0155","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/hmg\/8.4.621","article-title":"Excess of high activity monoamine oxidase A gene promoter alleles in female patients with panic disorder","volume":"8","author":"Deckert","year":"1999","journal-title":"Hum Mol Genet"},{"issue":"3","key":"10.1016\/j.braindev.2017.01.012_b0160","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1080\/08977190410001723308","article-title":"Brain-derived neurotrophic factor","volume":"22","author":"Binder","year":"2004","journal-title":"Growth Factors"},{"key":"10.1016\/j.braindev.2017.01.012_b0165","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.psc.2006.12.004","article-title":"Pharmacogenetic studies of antidepressant response: how far from the clinic?","volume":"30","author":"Perlis","year":"2007","journal-title":"Psychiatr Clin North Am"},{"key":"10.1016\/j.braindev.2017.01.012_b0170","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/mp.2008.116","article-title":"Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder","volume":"15","author":"Kato","year":"2010","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.braindev.2017.01.012_b0175","article-title":"The intersection of pharmacology, imaging, and genetics in the development of personalized medicine","volume":"17","author":"Gerretsen","year":"2009","journal-title":"Dialogues Clin Neurosci"},{"key":"10.1016\/j.braindev.2017.01.012_b0180","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1177\/0165025414538557","article-title":"A neurogenetics approach to defining differential susceptibility to institutional care","volume":"39","author":"Brett","year":"2015","journal-title":"Int J Behav Dev"},{"key":"10.1016\/j.braindev.2017.01.012_b0185","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.biopsych.2012.10.033","article-title":"The brain-derived neurotrophic factor Val66Met polymorphism predicts response to exposure therapy in posttraumatic stress disorder","volume":"73","author":"Felmingham","year":"2013","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.braindev.2017.01.012_b0190","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.brainres.2006.08.012","article-title":"Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder","volume":"1118","author":"Choi","year":"2006","journal-title":"Brain Res"},{"key":"10.1016\/j.braindev.2017.01.012_b0195","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1124\/dmd.104.002428","article-title":"Sertraline is matabolized by multiple cytrochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study","volume":"33","author":"Obach","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.braindev.2017.01.012_b0200","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1034\/j.1399-0004.2003.00115.x","article-title":"Association of autism severity with a monoamine oxidase A functional polymorphism","volume":"64","author":"Cohen","year":"2003","journal-title":"Clin Genet"},{"key":"10.1016\/j.braindev.2017.01.012_b0205","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1399-0004.2010.01471.x","article-title":"Autism severity is associated with child and maternal MAOA genotypes","volume":"79","author":"Cohen","year":"2011","journal-title":"Clin Genet"},{"key":"10.1016\/j.braindev.2017.01.012_b0210","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/ajmg.b.30738","article-title":"Cortical enlargement in autism is associated with a functional VNTR in the monoamine oxidase A gene","volume":"147B","author":"Davis","year":"2008","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"10.1016\/j.braindev.2017.01.012_b0215","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1176\/ajp.2006.163.12.2148","article-title":"5-HTTLPR genotype-specific phenotype in children and adolescents with autism","volume":"163","author":"Brune","year":"2006","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.braindev.2017.01.012_b0220","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1136\/jmg.2008.061796","article-title":"Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model","volume":"46","author":"Bilousova","year":"2009","journal-title":"J Med Genet"}],"container-title":["Brain and Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760417300128?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760417300128?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T23:51:46Z","timestamp":1568850706000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0387760417300128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0387760417300128"],"URL":"https:\/\/doi.org\/10.1016\/j.braindev.2017.01.012","relation":{},"ISSN":["0387-7604"],"issn-type":[{"value":"0387-7604","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular biomarkers predictive of sertraline treatment response in young children with fragile X syndrome","name":"articletitle","label":"Article Title"},{"value":"Brain and Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.braindev.2017.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}